We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Kalvista Pharmaceuticals Inc (KALV) USD0.001

Sell:$12.60 Buy:$12.67 Change: $0.80 (5.95%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.80 (5.95%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.80 (5.95%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). Plasma kallikrein is a serine protease enzyme, which is an early mediator of inflammation and edema. The body modulates the inflammatory effects of plasma kallikrein through a circulating inhibitor protein called C1-esterase inhibitor (C1-INH). The Company is primary focused on the development of the oral plasma kallikrein inhibitors for HAE. It has two drug program candidates in clinical trials. The Company’s DME program is focused on the development of an intravitreally administered small molecule plasma kallikrein inhibitor, KVD001, which completed a Phase II trial.

Contact details

55 Cambridge Pkwy Ste 901E
United States
+1 (857) 9990075

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$333.09 million
Shares in issue:
24.44 million
United States
US dollar

Key personnel

  • Thomas Crockett
    Chief Executive Officer, Director
  • Benjamin Palleiko
    Chief Financial Officer, Chief Business Officer
  • Michael Smith
    Senior Vice President - Development
  • Edward Feener
    Chief Scientific Officer
  • Christopher Yea
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.